SWOG clinical trial number
SWOG-9245

Central Lymphoma Repository Tissue Procurement Protocol for Relapse or Recurrent Disease, Ancillary

Closed
Phase
Abbreviated Title
ANCILLARY: Central Lymphoma Tissue Repository for Relapsed or Recurrent Disease
Activated
03/15/1993
Participants
NCORP, Members

Research committees

Lymphoma

Eligibility Criteria Expand/Collapse

For patients with prior registration to a Southwest Oncology Group-coordinated treatment protocol for previously untreated non-Hodgkin's lymphoma.

Other Clinical Trials

SWOG Clinical Trial Number
S2308

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
12%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase